Rifat Pamukcu

Rifat Pamukcu, M.D. is Chairman, President & CEO of Midway Pharmaceuticals, a start-up biotechnology company focused on diseases caused or influenced by gut bacteria and gut barrier dysfunction based on research performed at the University of Chicago and Michigan State University. Rifat was Founder, Director and CSO of Cell Pathways, Inc.(CPI), an emerging pharmaceutical company acquired by OSI Pharmaceuticals. He directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing over the course of a decade. He was also instrumental in obtaining over $140 million of capital and in the transformation of CPI to a public company. Dr. Pamukcu received his B.A. in Biology from The Johns Hopkins University and his M.D. degree from the University of Wisconsin School of Medicine. Dr. Pamukcu has authored over 110 journal articles, book chapters, and abstracts and is an inventor on over 280 issued or pending patents in the areas of drug discovery and development for cancer prevention, cancer treatment, and inflammatory bowel disease.